Friday, March 26, 2010

'Inhibition of Xenotropic Murine Leukemia Virus-Related Virus by APOBEC3 Protein

'Inhibition of Xenotropic Murine Leukemia Virus-Related Virus by
APOBEC3 Proteins and Antiviral Drugs'
Paprotka T, Venkatachari NJ, Chaipan C, Burdick R,
Delviks-Frankenberry KA, Hu WS, Pathak VK.

HIV Drug Resistance Program, National Cancer Institute at Frederick,
Viral Mutation Section and Viral Recombination Section, Frederick, MD
21702, USA.

J Virol. 2010 Mar 24. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20335265


Xenotropic murine leukemia virus-related virus (XMRV), a
gammaretrovirus, has been isolated from human prostate cancer tissue
and from activated CD4(+) T cells and B cells of patients with chronic
fatigue syndrome, suggesting an association between XMRV infection and
these two diseases. Since APOBEC3G (A3G) and APOBEC3F (A3F), which are
potent inhibitors of the murine leukemia virus and Vif-deficient human
immunodeficiency virus type 1 (HIV-1), are expressed in human CD4(+) T
cells and B cells, we sought to determine how XMRV evades suppression
of replication by APOBEC3 proteins. We found that expression of A3G,
A3F, or murine A3 in virus producing cells resulted in their virion
incorporation, inhibition of XMRV replication, and G-to-A
hypermutation of the viral DNA with all three APOBEC3 proteins.
Quantitation of A3G and A3F mRNA indicated that compared to human
T-cell lines CEM and H9, prostate cell lines LNCaP, and DU145
exhibited 50% lower A3F mRNA levels, whereas A3G expression in 22Rv1,
LNCaP and DU145 cells was nearly undetectable. A low frequency of XMRV
proviral genomes in LNCaP and DU145 cells were hypermutated with
mutation patterns consistent with A3F activity. XMRV proviral genomes
were extensively hypermutated upon replication in A3G/A3F-positive T
cells (CEM and H9) but not in A3G/A3F-negative cells (CEM-SS). We also
observed that XMRV replication was susceptible to nucleoside reverse
transcriptase (RT) inhibitors AZT and tenofovir, and integrase
inhibitor, raltegravir. In summary, the establishment of XMRV
infection in patients may be dependent on infection of
A3G/A3F-deficient cells and that cells expressing low levels of
A3G/A3F, such as prostate cancer cells, may be ideal producers of
infectious XMRV. Furthermore, anti-HIV-1 drugs AZT, tenofovir, and
raltegravir may be useful for treatment of XMRV infection.
 




No comments: